Stoke Therapeutics, Inc.
STOK
$31.27
-$0.04-0.13%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -162.41% | -144.30% | -452.70% | -45.09% | 8.61% |
| Total Depreciation and Amortization | 2.69% | -7.97% | -23.00% | -18.15% | -18.61% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 27.19% | 31.18% | 45.55% | 15.18% | 13.47% |
| Change in Net Operating Assets | 41.22% | -272.34% | 184.13% | 65.49% | -36,976.67% |
| Cash from Operations | -122.58% | -145.96% | -31.31% | -40.49% | -45.46% |
| Capital Expenditure | -1,183.12% | -132.24% | -452.38% | -28.16% | -234.78% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 107.41% | 270.34% | -7,164.92% | 130.86% | -68.11% |
| Cash from Investing | 106.07% | 271.88% | -7,555.56% | 130.31% | -68.19% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 245.13% | 6,037.34% | 16,157.22% | -61.76% | -99.54% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 245.13% | 6,037.34% | 16,157.22% | -61.76% | -99.54% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 73.66% | -49.30% | 103.79% | 58.23% | -1,263.78% |